Description
The 4FR6D3 monoclonal antibody specifically recognizes CD334 which is also known as Fibroblast growth factor receptor 4 (FGFR4), Tyrosine kinase related to fibroblast growth factor receptor (TKF), or JTK2. CD334 is a ~110 kDa type I transmembrane glycoprotein that belongs to the fibroblast growth factor receptor (FGFR) in the Ig superfamily (IgSF). The ligand-binding extracellular domain has three immunoglobulin-like C2-type domains followed by a transmembrane region and a cytoplasmic tail which contains a tyrosine kinase domain. CD334 serves as a high affinity receptor that dimerizes upon binding to fibroblast growth factors including FGF-1, -2, -4, -6, -8, -9, -16, -17, -18, and -19. This cell surface receptor tyrosine kinase is widely expressed on epithelial cells, fibroblasts and skeletal muscle cells and plays a role in the proliferation, differentiation, migration, and survival of these different cell types. Abnormal expression and activity of CD334 has been associated with a number of different cancers.
For optimal and reproducible results, BD Horizon Brilliant Stain Buffer should be used anytime two or more BD Horizon Brilliant dyes (including BD OptiBuild Brilliant reagents) are used in the same experiment. Fluorescent dye interactions may cause staining artifacts which may affect data interpretation. The BD Horizon Brilliant Stain Buffer was designed to minimize these interactions. More information can be found in the Technical Data Sheet of the BD Horizon Brilliant Stain Buffer (Cat. No. 563794).
Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. The antibody was conjugated with BD Horizon BUV737 under optimal conditions that minimize unconjugated dye and antibody.
1. This antibody was developed for use in flow cytometry.
2. The production process underwent stringent testing and validation to assure that it generates a high-quality conjugate with consistent performance and specific binding activity. However, verification testing has not been performed on all conjugate lots.
3. Researchers should determine the optimal concentration of this reagent for their individual applications.
4. An isotype control should be used at the same concentration as the antibody of interest.
5. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
6. For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
7. Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
8. BD Horizon Brilliant Stain Buffer is covered by one or more of the following US patents: 8,110,673; 8,158,444; 8,575,303; 8,354,239.
9. BD Horizon Brilliant Ultraviolet 737 is covered by one or more of the following US patents: 8,110,673; 8,158,444; 8,227,187; 8,575,303; 8,354,239.
